Fact checked byDrew Amorosi

Read more

October 23, 2024
1 min read
Save

Top in endocrinology: GLP-1s may reduce suicide risk; type 2 diabetes after COVID-19

Fact checked byDrew Amorosi
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adolescents prescribed a GLP-1 receptor agonist for obesity treatment reportedly had lower risk for suicidal thoughts and suicide attempts , according to researchers.

Among 3,456 adolescents using a GLP-1s, risk for suicidal ideation or suicide attempts was 33% lower compared with adolescents who received only a lifestyle intervention, according to study findings published in JAMA Pediatrics.

overweight child
Adolescents prescribed a GLP-1 receptor agonist for obesity treatment were less likely to have suicidal ideation or a suicide attempt compared with adolescents treated with a lifestyle intervention, according to researchers. Image: Adobe Stock

“Clinicians should assess each patient’s needs individually when deciding whether to prescribe GLP-1 receptor agonists, but based on our findings, there is no indication that the treatment poses an increased risk of suicidality in adolescents with obesity,” Liya Kerem, MD, MSc, pediatric endocrinologist at Hadassah Hebrew University Medical Center in Jerusalem, told Healio.

It was the top story in endocrinology last week.

In another top story, children and adolescents diagnosed with COVID-19 were develop new-onset type 2 diabetes more frequently than other respiratory illnesses.

Read these and more top stories in endocrinology below:

GLP-1 therapy may reduce suicidal ideation risk for adolescents with obesity

Adolescents with obesity prescribed a GLP-1 receptor agonist are less likely to have suicidal ideation or a suicide attempt than those with obesity treated with lifestyle intervention, according to new data. Read more.

New type 2 diabetes more likely in youth after COVID-19 vs. other respiratory diseases

Children and adolescents diagnosed with COVID-19 were more likely to develop new-onset type 2 diabetes than those who had other respiratory infections, according to data published in JAMA Network Open. Read more.

Parathyroid hormone therapy normalizes calcium for most with hypoparathyroidism

Most adults with hypoparathyroidism achieved normal serum calcium levels with palopegteriparatide at 1 year without supplemental vitamin D or calcium, according to data from a phase 3 open-label extension study. Read more.

Duodenal mucosal renewal plus semaglutide may lower HbA1c long term without insulin use

A novel duodenal mucosal renewal procedure followed by once-weekly semaglutide could allow adults with type 2 diabetes to maintain glycemic control without insulin therapy, according to a speaker at United European Gastroenterology Week. Read more.

Screening, referrals needed for overlooked ‘third pillar’ of PCOS: Psychosocial symptoms

After years of advocacy and research, clinicians increasingly recognize the physical symptoms of polycystic ovary syndrome. Yet, many women with PCOS have a range of serious psychosocial comorbidities that often go unaddressed. Read more.